drugset / Trial / NCT04430894
KRDI in Transplant-Eligible MM
Phase 2
Active not recruiting
50 enrolled
Massachusetts General Hospital
Amgen · collabSanofi · collab
Non-randomizedSingle-groupSingle-blindTreatment
Summary
This research study is testing the efficacy of an experimental drug combination for people with newly diagnosed multiple myeloma that are eligible for a stem cell transplant. The names of the study drugs involved in this study are: * Carfilzomib * Isatuximab * Lenalidomide * Dexamethasone
Timeline
- Start
- 2020-07-10
- Primary completion
- 2022-07-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 56 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Isatuximab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |